Pillar Biosciences
Pillar Biosciences Receives CMS Coverage for Pan-Cancer CDx Assay
The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.
Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes
Premium
Memorial Sloan Kettering Cancer Center is among the first healthcare systems to implement the rapid sequencing assay, which can consolidate single-gene tests.
Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe
AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.
FDA Approves Pillar Biosciences Pan-Cancer NGS Test for Solid Tumor Profiling
Previously approved for guiding EGFR- and KRAS-targeted therapy in specific tumor types, OncoReveal CDx can now be sold for general solid tumor profiling.
Illumina, Pillar Biosciences Ink Global Distribution Agreement for Cancer Dx Assays
The firms said their distribution deal will facilitate the integration of Pillar's precision oncology assays and Illumina's sequencers.